CI monoclonal antibodies ("-mab") |
| ||||||||
---|---|---|---|---|---|---|---|---|---|
Tyrosine kinase inhibitors ("-nib") |
| ||||||||
Other |
|
Endogenous |
| ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Exogenous |
Intracellular (initiation) |
| ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Intracellular (reception) |
| ||||||||||||||
Extracellular |
| ||||||||||||||
Unsorted |
|
pyrazolones / pyrazolidines | |
---|---|
salicylates | |
acetic acid derivatives and related substances | |
oxicams | |
propionic acid derivatives ( profens) |
|
n-arylanthranilic acids ( fenamates) | |
COX-2 inhibitors (coxibs) | |
other | |
NSAID combinations | |
Key: underline indicates initially developed first-in-class compound of specific group; #
WHO-Essential Medicines; †
withdrawn drugs; ‡
veterinary use. | |
Specific
antirheumatic products / DMARDs (
M01C) | |
---|---|
Quinolines | |
Gold preparations | |
Other | |
|
Anti-inflammatory preparations, non-steroids |
| ||||||
---|---|---|---|---|---|---|---|
Capsaicin derivatives | |||||||
Other |
Skeletal
muscle relaxants (
M03) | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Peripherally acting (primarily antinicotinic, NMJ block) |
| ||||||||||||||
Centrally acting |
| ||||||||||||||
Directly acting |
Uricosurics |
| ||||
---|---|---|---|---|---|
Xanthine oxidase inhibitors |
| ||||
Mitotic inhibitors | |||||
Other | |||||
|
Drugs for treatment of
bone diseases (
M05) | |
---|---|
Bisphosphonates | |
Bone morphogenetic proteins | |
Other |
|
Other drugs for disorders of the
musculo-skeletal system (
M09) | |
---|---|
Quinine and derivatives | |
Enzymes | |
Gene therapies | |
Antisense oligonucleotides | |
Glucocorticoids | |
Histone deacetylase inhibitors | |
Other | |
|
Inhalational | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Injection |
| ||||||||||||||
|
Esters by acid |
| ||||||
---|---|---|---|---|---|---|---|
Amides | |||||||
Combinations | |||||||
|
Opioids |
| ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Paracetamol-type | |||||||||||||||||
NSAIDs |
| ||||||||||||||||
Cannabinoids | |||||||||||||||||
Ion channel modulators |
| ||||||||||||||||
Myorelaxants | |||||||||||||||||
Others | |||||||||||||||||
|
Antimigraine preparations (
N02C) | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Analgesic/abortive |
| ||||||||||||||||
Prophylactic |
| ||||||||||||||||
|
GABAergics |
| ||||||
---|---|---|---|---|---|---|---|
Channel modulators |
| ||||||
Others |
| ||||||
|
Dopaminergics |
| ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Anticholinergics | |||||||||||
Others | |||||||||||
|
D1-like |
| ||||||
---|---|---|---|---|---|---|---|
D2-like |
| ||||||
Typical |
|
---|---|
Disputed | |
Atypical | |
Others |
|
|
Anxiolytics (
N05B) | |
---|---|
5-HT1ARTooltip 5-HT1A receptor agonists | |
GABAARTooltip GABAA receptor PAMsTooltip positive allosteric modulators |
|
Hypnotics | |
Gabapentinoids ( α2δ VDCC blockers) | |
Antidepressants |
|
Antipsychotics | |
Sympatholytics ( Antiadrenergics) |
|
Others | |
|
GABAA |
| ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
GABAB | |||||||||||||||||||||||||
H1 |
| ||||||||||||||||||||||||
α2-Adrenergic | |||||||||||||||||||||||||
5-HT2A |
| ||||||||||||||||||||||||
Melatonin | |||||||||||||||||||||||||
Orexin | |||||||||||||||||||||||||
α2δ VDCC | |||||||||||||||||||||||||
Others |
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
|
N06BA Centrally acting sympathomimetics | |||||||||
---|---|---|---|---|---|---|---|---|---|
N06BC Xanthine derivatives | |||||||||
N06BX Other psychostimulants and nootropics | |||||||||
|
AChE inhibitor medications | |
---|---|
Other medications | |
Experimental BACE inhibitors |
|
Treatment of
drug dependence (
N07B) | |
---|---|
Nicotine dependence |
|
Alcohol dependence | |
Opioid dependence | |
Benzodiazepine dependence |
|
Other nervous system drugs (
N07X) | |
---|---|
Stroke | |
ALS | |
Other | |
|
Alveo- late |
| ||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Stramen- opile | |||||||||||||||||||||||||||||||||||||||||||||||
|
Discicristata |
| ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Trichozoa |
| ||||||||||
|
Entamoeba |
| ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Acanthamoeba | |||||||||||||||||
|
Antiplatyhelmintic agents |
| ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Antinematodal agents (including macrofilaricides) |
| ||||||||||||||
|
Insecticide/ pediculicide |
| ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Acaricide/ miticide/ scabicide |
| ||||||||||||||
|
Carbamates | |
---|---|
Inorganic compounds | |
Insect growth regulators | |
Neonicotinoids | |
Organochlorides | |
Organophosphorus |
|
Pyrethroids |
|
Ryanoids | |
Other chemicals |
|
Metabolites | |
Biopesticides |
Decongestants and other nasal preparations (
R01) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Topical |
| ||||||||||
Systemic use: Sympathomimetics | |||||||||||
|
Adrenergics, inhalants |
| ||||||||
---|---|---|---|---|---|---|---|---|---|
Glucocorticoids | |||||||||
Anticholinergics/ muscarinic antagonist | |||||||||
Mast cell stabilizers | |||||||||
Xanthines | |||||||||
Eicosanoid inhibition |
| ||||||||
Others/unknown | |||||||||
Combination products |
| ||||||||
|
Expectorants | |||||
---|---|---|---|---|---|
Mucolytics | |||||
Cough suppressants |
| ||||
|
Benzimidazoles ( *) | |
---|---|
Diarylmethanes |
|
Ethylenediamines | |
Tricyclics | |
Others |
|
For topical use |
Other
respiratory system products (
R07) | |
---|---|
Lung surfactants | |
Respiratory stimulants | |
5-HT4 receptor agonists | |
Other agents for treating respiratory depression |
Antibiotics |
|
---|---|
Sulfonamides | |
Antivirals | |
Fluoroquinolones | |
Other |
Sympathomimetics | |||||||
---|---|---|---|---|---|---|---|
Parasympathomimetics |
| ||||||
Carbonic anhydrase inhibitors/ ( sulfonamides) | |||||||
Beta blocking agents | |||||||
Prostaglandin analogues (F2α) | |||||||
Other agents |
Anti neovascularisation agents |
---|
Nervous system |
| ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Circulatory system |
| ||||||||||||||
Other |
| ||||||||||||||
Emetic | |||||||||||||||
|
Copper | |
---|---|
Iron | |
Lead | |
Thallium | |
Other | |
|
Folic acid / methotrexate |
|
---|---|
Uric acid ( TLS) | |
Acrolein / nitrogen mustards | |
Iron / anthracyclines | |
Alkylating agents | |
Keratinocyte growth factor | |
Other |
Treatment of hypercalcemia | |
---|---|
Treatment of hypoglycaemia | |
Medical gases |
Diagnostic agents (
V04) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Digestive system |
| ||||||||||||
Endocrine system |
| ||||||||||||
Tuberculosis | |||||||||||||
Renal function |
X-ray and CT |
| ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MRI |
| ||||||||||||
Ultrasound |
| ||||||||||||
|
Diagnostic
radiopharmaceuticals (
V09) | |||||
---|---|---|---|---|---|
Central nervous system | |||||
Skeletal system | |||||
Renal | |||||
Gastrointestinal/ Hepatic | |||||
Respiratory system | |||||
Cardiovascular system | |||||
Inflammation/ infection | |||||
Tumor | |||||
Adrenal cortex |
| ||||
Radionuclides (including tracers) |
| ||||
Therapeutic
radiopharmaceuticals (
V10) | |||||
---|---|---|---|---|---|
Pain palliation | |||||
Adrenergic tumors | |||||
CD20 antibodies | |||||
Radionuclides |
| ||||